Morgan Stanley Maintains Equal-Weight on PBF Energy, Raises Price Target to $36
Morgan Stanley analyst Connor Lynagh maintains PBF Energy (NYSE:PBF) with a Equal-Weight and raises the price target from $34 to $36.
Morgan Stanley Maintains Equal-Weight on NuVasive, Lowers Price Target to $54
Morgan Stanley analyst Drew Ranieri maintains NuVasive (NASDAQ:NUVA) with a Equal-Weight and lowers the price target from $62 to $54.
Morgan Stanley Maintains Underweight on NeuroPace, Lowers Price Target to $5.5
Morgan Stanley analyst Drew Ranieri maintains NeuroPace (NASDAQ:NPCE) with a Underweight and lowers the price target from $6 to $5.5.
Morgan Stanley Maintains Equal-Weight on Neurocrine Biosciences, Raises Price Target to $102
Morgan Stanley analyst Jeffrey Hung maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Equal-Weight and raises the price target from $100 to $102.
Morgan Stanley Maintains Equal-Weight on Montrose Environmental Gr, Lowers Price Target to $51
Morgan Stanley analyst Matthew Sharpe maintains Montrose Environmental Gr (NYSE:MEG) with a Equal-Weight and lowers the price target from $56 to $51.
Morgan Stanley Maintains Equal-Weight on Medtronic, Lowers Price Target to $103
Morgan Stanley analyst Cecilia Furlong maintains Medtronic (NYSE:MDT) with a Equal-Weight and lowers the price target from $114 to $103.
Morgan Stanley Maintains Overweight on Marathon Petroleum, Raises Price Target to $120
Morgan Stanley analyst Connor Lynagh maintains Marathon Petroleum (NYSE:MPC) with a Overweight and raises the price target from $115 to $120.
Why This 10X Genomics Analyst Is Turning Bearish, Slashing Price Target
10X Genomics Inc (NASDAQ: TXG) reported preliminary second-quarter revenues Thursday that were meaningfully below the consensus estimates.
Morgan Stanley Maintains Equal-Weight on Lennox International, Lowers Price Target to $222
Morgan Stanley analyst Joshua Pokrzywinski maintains Lennox International (NYSE:LII) with a Equal-Weight and lowers the price target from $238 to $222.
Morgan Stanley Maintains Overweight on Legend Biotech, Raises Price Target to $63
Morgan Stanley analyst Matthew Harrison maintains Legend Biotech (NASDAQ:LEGN) with a Overweight and raises the price target from $55 to $63.